- Home
- GE vs ABBV Comparison
GE vs ABBV Comparison
Compare GE & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GE | ABBV |
|---|---|---|
| Founded | 1892 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 318.8B | 375.7B |
| IPO Year | 2008 | 2012 |
Fundamental Metrics
Financial Performance| Metric | GE | ABBV |
|---|---|---|
| Price | $283.38 | $197.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 19 |
| Target Price | ★ $345.25 | $250.94 |
| AVG Volume (30 Days) | ★ 5.9M | 4.6M |
| Earning Date | 04-21-2026 | 04-29-2026 |
| Dividend Yield | 0.66% | ★ 3.48% |
| EPS Growth | ★ 35.89 | N/A |
| EPS | 1.81 | ★ 2.36 |
| Revenue | $45,855,000,000.00 | ★ $61,160,000,000.00 |
| Revenue This Year | $8.37 | $11.87 |
| Revenue Next Year | $10.25 | $8.12 |
| P/E Ratio | $157.18 | ★ $84.38 |
| Revenue Growth | ★ 18.48 | 8.57 |
| 52 Week Low | $196.86 | $180.25 |
| 52 Week High | $348.48 | $244.81 |
Technical Indicators
Market Signals| Indicator | GE | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 42.54 | 33.00 |
| Support Level | $262.74 | $186.13 |
| Resistance Level | $314.16 | $234.00 |
| Average True Range (ATR) | 10.11 | 4.98 |
| MACD | -1.82 | -0.64 |
| Stochastic Oscillator | 28.88 | 8.16 |
Price Performance
Historical ComparisonAbout GE General Electric Company
GE Aerospace is the global leader in designing, manufacturing, and servicing commercial aircraft turbine engines, along with partner Safran in their CFM joint venture. With its massive global installed base of nearly 80,000 commercial and military engines, GE Aerospace earns most of its profits on recurring service revenue of that equipment, which operates for decades. GE Aerospace is the remaining core business of the company formed in 1892 with historical ties to American inventor Thomas Edison; that company became a storied conglomerate with peak revenue of $130 billion in 2000 until GE spun off its appliance, finance, healthcare, and wind and power businesses between 2016 and 2024.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.